Highlights Evolus, Inc.

Equities

EOLS

US30052C1071

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
13.3 ^USD	+0.61%		+16.36%	+26.31%

Apr. 26	AbbVie raises annual profit forecast on strong Skyrizi sales	RE
Apr. 17	Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AbbVie raises annual profit forecast on strong Skyrizi sales	Apr. 26	RE
Evolus, Inc. Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra- Strength" 40U Formulation of Jeuveau	Apr. 17	CI
Evolus Q4 Net Loss Narrows, Revenue Increases; 2024 Revenue Guidance Affirmed; Shares Fall After Hours	Mar. 07	MT
Evolus, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07	CI
Earnings Flash (EOLS) EVOLUS Posts Q4 Revenue $61M, vs. Street Est of $61.1M	Mar. 07	MT
Evolus, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 07	CI
Evolus, Inc. Reiterates Earnings Guidance for the Full Year 2024	Mar. 07	CI
AbbVie profit beats estimates as Humira, Botox sales weather hit from rivals	Feb. 02	RE
Evolus Reports Higher Q4, 2023 Preliminary Revenue, Expects 2024 Revenue to Rise as Much as 31%; Shares Climb	Jan. 16	MT
Evolus, Inc. Announces Earnings Guidance for 2024	Jan. 16	CI
Evolus Signs Licensing Deal With Symatese to Distribute Dermal Fillers in UK, Europe	Dec. 20	MT
Evolus, Inc. Enters into Licensing Agreement with Symatese to Exclusively Distribute Next Generation Dermal Fillers in Europe	Dec. 20	CI
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	Dec. 12	MT
US Consumer group seeks stronger warnings on Botox, similar treatments	Dec. 12	RE
Evolus, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (EOLS) EVOLUS Posts Q3 Revenue $50M, vs. Street Est of $44.4M	Nov. 07	MT
Evolus, Inc. Raises Earnings Guidance for the Full Year 2023	Nov. 07	CI
Evolus, Inc. Announces Results from the Phase 2 Clinical Study Evaluating the "Extra- strength" 40U Dose for Extended Duration of Jeuveau	Nov. 06	CI
Evolus, Inc. Unveils New Branding for Product Jeuveau to Reflect Growing and Evolving Consumers	23-08-08	CI
Evolus, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Evolus, Inc.

Equities

EOLS

US30052C1071

Highlights

Filters